174 related articles for article (PubMed ID: 27748274)
21. [Value of Multiparameter Flow Cytometry in Diagnosis of Non-Hodgkin's Lymphoma].
Li YP; Zhang ZH; Zhao FT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):102-5. PubMed ID: 26913403
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.
Laane E; Tani E; Björklund E; Elmberger G; Everaus H; Skoog L; Porwit-MacDonald A
Cytometry B Clin Cytom; 2005 Mar; 64(1):34-42. PubMed ID: 15669024
[TBL] [Abstract][Full Text] [Related]
23. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
24. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.
Walter K; Cockerill PN; Barlow R; Clarke D; Hoogenkamp M; Follows GA; Richards SJ; Cullen MJ; Bonifer C; Tagoh H
Oncogene; 2010 May; 29(20):2927-37. PubMed ID: 20208555
[TBL] [Abstract][Full Text] [Related]
25. In vivo footprinting and mutational analysis of the proximal CD19 promoter reveal important roles for an SP1/Egr-1 binding site and a novel site termed the PyG box.
Riva A; Wilson GL; Kehrl JH
J Immunol; 1997 Aug; 159(3):1284-92. PubMed ID: 9233624
[TBL] [Abstract][Full Text] [Related]
26. PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.
Feldman AL; Law ME; Inwards DJ; Dogan A; McClure RF; Macon WR
Mod Pathol; 2010 Apr; 23(4):593-602. PubMed ID: 20118907
[TBL] [Abstract][Full Text] [Related]
27. [Immunophenotyping in the differential diagnosis of malignant non-hodgkin's lymphomas].
Dzembak TM; Gurkalo VK; Gershanovich ML
Vopr Onkol; 1996; 42(5):63-6. PubMed ID: 9064906
[TBL] [Abstract][Full Text] [Related]
28. Identification of Pax5 as a target of MTA1 in B-cell lymphomas.
Balasenthil S; Gururaj AE; Talukder AH; Bagheri-Yarmand R; Arrington T; Haas BJ; Braisted JC; Kim I; Lee NH; Kumar R
Cancer Res; 2007 Aug; 67(15):7132-8. PubMed ID: 17671180
[TBL] [Abstract][Full Text] [Related]
29. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis.
Nutt SL; Eberhard D; Horcher M; Rolink AG; Busslinger M
Int Rev Immunol; 2001 Feb; 20(1):65-82. PubMed ID: 11342298
[TBL] [Abstract][Full Text] [Related]
30. Loss of CD19 expression in B-cell neoplasms.
Masir N; Marafioti T; Jones M; Natkunam Y; Rüdiger T; Hansmann ML; Mason DY
Histopathology; 2006 Feb; 48(3):239-46. PubMed ID: 16430470
[TBL] [Abstract][Full Text] [Related]
31. [Application of multiparameter flow cytometry in diagnosis of non-Hodgkin lymphoma].
He FJ; Xie Y; Li JY; Yong WB; Lu AP; Zhu J
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):203-8. PubMed ID: 16776976
[TBL] [Abstract][Full Text] [Related]
32. [T-cell-rich B-cell lymphoma: multifactorial study of 4 cases].
Moreno MM; Fernández-Flores A; Paradela A; Rodríguez JM; Ageitos A; Gonzalo I; Marcos B; Robledo M; Rivas C
Sangre (Barc); 1995 Dec; 40(6):471-7. PubMed ID: 8850230
[TBL] [Abstract][Full Text] [Related]
33. Genotype study of non-Hodgkin's lymphoma.
Pitera R; Pitera JE; Mufti GJ; Salisbury JR
Pathol Res Pract; 1995 Jun; 191(5):444-55. PubMed ID: 7479363
[TBL] [Abstract][Full Text] [Related]
34. [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma].
Zhou X; Zhao T; Qi Z; Liu G; Zhu M
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1532-5. PubMed ID: 12609061
[TBL] [Abstract][Full Text] [Related]
35. EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.
Bullerwell CE; Robichaud PP; Deprez PML; Joy AP; Wajnberg G; D'Souza D; Chacko S; Fournier S; Crapoulet N; Barnett DA; Lewis SM; Ouellette RJ
Sci Rep; 2021 Jan; 11(1):1537. PubMed ID: 33452395
[TBL] [Abstract][Full Text] [Related]
36. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
Stauder R; Eisterer W; Thaler J; Günthert U
Blood; 1995 May; 85(10):2885-99. PubMed ID: 7537983
[TBL] [Abstract][Full Text] [Related]
37. Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.
García-Sanz R; Vargas Montero M; Gonzalez Díaz M; del Carmen M; Santos C; Balanzategui Echevarria A; Flores Corral T; Hernández Martín JM; Caballero Barrigón MD; San Miguel JF
Haematologica; 1998 Mar; 83(3):209-16. PubMed ID: 9573674
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of PAX5 in oral carcinogenesis.
Norhany S; Kouzu Y; Uzawa K; Hayama M; Higo M; Koike H; Kasamatu A; Tanzawa H
Oncol Rep; 2006 Nov; 16(5):1003-8. PubMed ID: 17016584
[TBL] [Abstract][Full Text] [Related]
39. [Effect of pax5 gene blocked by RNAi on biological characteristics of B cell malignant lymphoma].
Yuan XL; Zhang B; Jiang LM; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):799-803. PubMed ID: 18718064
[TBL] [Abstract][Full Text] [Related]
40. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
